41 suspended. 41 Phase 2, 14 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 41 | Suspended 41 |
| Phase 1 | 14 | Suspended 14 |
| Phase 3 | 4 | Suspended 4 |
Follow Digestive System Neoplasms: new trials by email Literature Review of Digestive System Neoplasms trials Research Report on Digestive System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer CA102N, TAS-102, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Suspended | Holy Stone Healthcare Co., Ltd | 100 | 2027-12-01 | 2026-09-18 |
| Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC Rintatolimod - Pancreatic Cancer | Phase 2 | Suspended | AIM ImmunoTech Inc. | 90 | 2027-08-01 | 2026-08-19 |
| TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer TGFBR2 KO CAR27/IL-15 NK cells - Pancreatic Cancer | Phase 1 / Phase 2 | Suspended | M.D. Anderson Cancer Center | 37 | 2026-05-26 | 2026-07-31 |
| Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites Stereotactic body radiation therapy (SBRT), Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.) - Metastatic Colorectal Cancer, Oligometastatic Disease | Phase 2 | Suspended | UMC Utrecht | 93 | 2025-12-01 | 2025-03-28 |
| Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer Trifluridine/tipiracil, Oxaliplatin - Biliary Tract Cancer, Biliary Tract Neoplasms | Phase 2 | Suspended | Case Comprehensive Cancer Center | 27 | 2025-12-01 | 2026-10-20 |
| SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma Systemic therapy, Radiotherapy - Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Suspended | Shandong Cancer Hospital and Institute | 184 | 2025-11-30 | 2026-10-15 |
| HEARTS Trial for Thoracic Cancers MRgART, LINAC - Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III | Phase 2 | Suspended | University of Wisconsin, Madison | 60 | 2025-10-08 | 2026-10-30 |
| Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma Adebrelimab - Adebrelimab, Hepatocellular Carcinoma | Phase 2 | Suspended | Tianjin Medical University Cancer Institute and Hospital | 40 | 2024-05-01 | 2026-05-29 |
| Endorectal Brachytherapy for Rectal Cancer Endorectal brachytherapy - Locally Advanced Rectal Carcinoma | Phase 2 | Suspended | University Hospital, Bordeaux | 31 | 2024-01-31 | 2025-08-01 |
| Immunotherapy for Advanced Liver Cancer AlloStim® immunotherapy, FOLFOX regimen, Sorafenib - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Suspended | Mirror Biologics, Inc. | 150 | 2023-08-01 | 2025-10-23 |
| Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients 5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule - Stage II Colon Cancer, Stage III Colon Cancer | Phase 2 | Suspended | Gruppo Oncologico del Nord-Ovest | 477 | 2023-05-17 | 2026-02-03 |
| Switch Maintenance in Pancreatic ZIMBERELIMAB, DOMVANALIMAB, APX005M - Pancreatic Cancer, Adenocarcinoma of the Pancreas | Phase 1 / Phase 2 | Suspended | James Cleary, MD, PhD | 46 | 2022-11-30 | 2026-06-04 |
| A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer VS-6766/avutometinib, Cetuximab, Pill Diary - Colorectal Cancer, Colorectal Adenocarcinoma | Phase 1 / Phase 2 | Suspended | University of Chicago | 53 | 2022-08-22 | 2026-05-08 |
| A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer camrelizumab+chemotherapy, Chemotherapy - Gastric Cancer | Phase 1 / Phase 2 | Suspended | Shanghai Minimally Invasive Surgery Center | 100 | 2022-07-01 | 2024-03-07 |
| Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) - Cancer of Rectum | Phase 2 | Suspended | Rutgers, The State University of New Jersey | 38 | 2022-05-13 | 2025-12-04 |
| A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 ChAdOx1-MAGEA3-NYESO (Route = IM injection, Dose = 5×10^10 vp), MVA-MAGEA3 (Route = IM injection, Dose = 1.3×10^8 pfu), Standard of care treatment - Non-small Cell Lung Cancer (NSCLC), Squamous Oesophageal Cancer | Phase 1 / Phase 2 | Suspended | Cancer Research UK | 15 | 2021-10-15 | 2026-04-06 |
| A Study of ABTL0812 in Pancreatic Cancer ABTL0812, Gemcitabine and nab-paclitaxel - Pancreatic Cancer | Phase 1 / Phase 2 | Suspended | Ability Pharmaceuticals SL | 60 | 2021-04-26 | 2025-10-01 |
| EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden Liver-resection or ablation, 2nd line chemotherapy - Liver Metastases, Colorectal Cancer | Phase 2 | Suspended | Oslo University Hospital | 62 | 2021-03-23 | 2026-10-22 |
| Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 92 | 2021-01-11 | 2026-10-20 |
| A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE - Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma | Phase 2 | Suspended | Thomas Jefferson University | 100 | 2020-11-10 | 2026-10-28 |
Showing 20 of 41. Sign in to see all of them.
Pancreatic Neoplasms (12) · Colorectal Neoplasms (9) · Stomach Neoplasms (7) · Carcinoma, Hepatocellular (5) · Neoplasms (4) · Rectal Neoplasms (4) · Colonic Neoplasms (3) · Esophageal Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Peritoneal Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Biliary Tract Neoplasms (1)
Digestive System Diseases (41) · Neoplasms by Site (41) · Neoplasms (37) · Gastrointestinal Diseases (24) · Gastrointestinal Neoplasms (23) · Intestinal Diseases (15) · Intestinal Neoplasms (15) · Rectal Diseases (13) · Endocrine Gland Neoplasms (12) · Endocrine System Diseases (12) · Pancreatic Diseases (12) · Colonic Diseases (11) · Neoplasms by Histologic Type (11) · Neoplasms, Glandular and Epithelial (10)
Gemcitabine (4) · Bevacizumab (3) · Capecitabine (3) · Irinotecan (3) · Oxaliplatin (3) · S 1 (combination) (3) · trifluridine tipiracil drug combination (3) · Drug Therapy (2) · Fluorouracil (2) · Leucovorin (2) · Radiation (2) · Radiotherapy (2) · 130-nm albumin-bound paclitaxel (1) · ABTL0812 (1) · Albumin-Bound Paclitaxel (1)
Hokkaido Gastrointestinal Cancer Study Group (3) · The Clatterbridge Cancer Centre NHS Foundation Trust (2) · AIM ImmunoTech Inc. (1) · ARCA Biopharma, Inc. (1) · Ability Pharmaceuticals SL (1) · CMED HIFU Development Corporation (1) · Cancer Research UK (1) · Case Comprehensive Cancer Center (1) · Fudan University (1) · Gruppo Oncologico del Nord-Ovest (1) · HRYZ Biotech Co. (1) · Holy Stone Healthcare Co., Ltd (1) · Hospital General Universitario Gregorio Marañon (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · James Cleary, MD, PhD (1)
United States (16) · China (8) · France (4) · Japan (3) · United Kingdom (3) · Italy (2) · Spain (2) · Germany (1) · Malaysia (1) · Netherlands (1) · Norway (1) · Thailand (1)
Masahiro Asaka, MD, PhD (2) · Andrew Poklepovic, MD (1) · Ardaman S. Shergill, MD (1) · Carri Glide-Hurst, PhD, DABR, FAAPM (1) · Chen Ming, MD (1) · Daniel H Palmer, BSC, PhD (1) · Daniel Lin, MD (1) · Daniel Palmer, PhD, MD (1) · David R Strayer, MD (1) · Fiona Blackhall, Prof (1) · Guus Bol, Dr. (1) · Harald Hoensch, Professor (1) · James Cleary, MD, PhD (1) · Jin Li, PhD (1)
PMID 20510306, PMID 24006012, PMID 24635869, PMID 28069018, PMID 29800971, PMID 31182448, PMID 32557715, PMID 33593311, PMID 34482636, PMID 36331676
2009 (1), 2017 (1), 2019 (1), R01HL153720 (1), UM1CA186691 (1)